SaakshiKhattriMDBoard certified Rheumatologist

Associate Professor and Fellowship Director, Department of Dermatology, Icahn School of Medicine at Mount Sinai, Adjunct Faculty, Department of Investigative Dermatology, Rockefeller University

Request Appointment

Overview of Dr. Khattri

Dr. Saakshi Khattri is a dermatologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital, Mount Sinai West, Mount Sinai Morningside, Mount Sinai Hospital of Queens, and Rockefeller University Hospital. She received her medical degree from Maulana Azad Medical College and has been in practice 16 years. She is one of 347 doctors at The Mount Sinai Hospital and one of 6 doctors at Rockefeller University Hospital who specialize in Dermatology. She has more than 50 publications and over 500 citings.

Office
5, EAST 98TH STREET
5TH FLOOR- DERMATOLOGY
New York, NY 10029
Book by Phone+1(901) 660-2906

Education & Training

Icahn School of Medicine at Mount SinaiResidency, Dermatology, 2015 - 2018
Rockefeller University HospitalPost-Doctoral Fellowship, 2013 - 2015
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Rheumatology, 2010 - 2012
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2007 - 2010
Maulana Azad Medical CollegeClass of 2006

Certifications & Licensure

NY State Medical License 2018 - 2026
CA State Medical License 2014 - 2020
American Board of Dermatology Dermatology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Clinical Trials

A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin Start of enrollment: 2013 Jun 01
Completed
Not Applicable
Spesolimab in Pyoderma Gangrenosum Start of enrollment: 2023 Sep 26
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period Start of enrollment: 2023 Nov 06
Recruiting
Phase 3
Roles: Principal Investigator

Publications & Presentations

PubMed

167 citations
Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
Tali Czarnowicki, Juana Gonzalez, Avner Shemer, Dana Malajian, Hui Xu
The Journal of Allergy and Clinical Immunology. 2015-07-01
19 citations
Undertreatment of Disease Activity in Systemic Lupus Erythematosus Patients with Endstage Renal Failure Is Associated with Increased All-cause Mortality
Anna Broder, Saakshi Khattri, Ruchika Patel, Chaim Putterman
The Journal of Rheumatology. 2011-11-01
220 citations
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatment...
Emma Guttman-Yassky, Patrick M. Brunner, Avidan U. Neumann, Saakshi Khattri, Ana B. Pavel
Journal of the American Academy of Dermatology. 2018-05-01

Press Mentions

‘Pristine’ Safety Profile Sets TYK2i Apart from JAK ‘Baggage’ in Psoriatic Disease, LupusAugust 16th, 2024
Weighing the Risks and Benefits of Each New MedicationOctober 14th, 2022
MNT Investigates: A Closer Look at IL-23 Inhibitors for PsoriasisJuly 19th, 2022
Join now to see all